“Canatu has extensive potential in advanced CNT applications. We have followed Canatu’s development for some time and are delighted to combine with Canatu at a stage where it aims to accelerate its business in semiconductor and automotive applications and is entering the emerging medical diagnostics market. We are impressed by Canatu’s technological competencies, which stem from the long heritage of Finnish research in nanomaterials, its experienced management, and attractive financial profile, all of which lay a strong foundation to create value for our current and new shareholders.”, comments Tuomo Vähäpassi, founding partner and CEO of Lifeline SPAC I.
“Canatu has extensive potential in advanced CNT applications. We have followed Canatu’s development for some time and are delighted to combine with Canatu at a stage where it aims to accelerate its business in semiconductor and automotive applications and is entering the emerging medical diagnostics market. We are impressed by Canatu’s technological competencies, which stem from the long heritage of Finnish research in nanomaterials, its experienced management, and attractive financial profile, all of which lay a strong foundation to create value for our current and new shareholders.” Comments Juha Kokkonen, CEO of Canatu.
Read more HLP commentary on the case Back to transactions